In this largest to-date genetic analysis of anti-drug antibody (ADA) response to a therapeutic monoclonal antibody (MAb), genome-wide association was performed for five measures of ADA status among 8844 individuals randomized to bococizumab, which targets PCSK9 for LDL-C lowering and cardiovascular protection. Index associations prioritized specific amino acid substitutions at the DRB1 and DQB1 MHC class II genes rather than canonical haplotypes. Two clusters of missense variants at DRB1 were associated with general ADA measures (residues 9, 11, 13; and 96, 112, 120, 180) and a third cluster of missense variants in DQB1 was associated with ADA measures including neutralizing antibody (NAb) titers (residues 66, 67, 71, 74, 75). The structural disposition of the missense substitutions implicates peptide antigen binding and CD4 effector function, mechanisms that are potentially generalizable to other therapeutic mAbs.Clinicaltrials.gov: NCT01968954, NCT01968967, NCT01968980, NCT01975376, NCT01975389, NCT02100514.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917227 | PMC |
| http://dx.doi.org/10.1038/s41598-022-07997-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison between monotest and traditional batch-based ELISA assays for therapeutic drug monitoring of infliximab and adalimumab levels and anti-drug antibodies.
Clin Chem Lab Med
January 2025
Product Development and Support, Progenika Biopharma, SA, Derio, Spain.
Objectives: To compare a new ready-to-use monotest immunoassay, CHORUS Promonitor, for the quantification of serum biological drug levels and anti-drug antibodies of anti-TNF agents, against the reference batch-based ELISA test, Promonitor.
Methods: Blood samples were collected from patients treated with anti-TNF agents, infliximab (IFX) or adalimumab (ADL). IFX and ADL levels, as well as anti-IFX and anti-ADL antibodies were quantified and compared between the standard ELISA reference test, Promonitor, and the automated monotest ELISA assay, CHORUS Promonitor.
Adalimumab Autoantibodies in Uveitis Patients: Do We Need Routine Drug Monitoring?
Biomedicines
December 2024
Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Background: Adalimumab, an anti-TNF-α biologic agent, has emerged as a principal treatment option for patients with non-infectious uveitis. The influence of adalimumab anti-drug antibodies (AAA) on the efficacy of adalimumab therapy is not yet fully understood. We aim to understand their clinical implications in the context of therapeutic drug monitoring and the factors contributing to the formation of these antibodies.
View Article and Find Full Text PDFBrolucizumab and Platelet Activation and Reactivity.
Curr Eye Res
January 2025
Centre for Ophthalmology, Eberhard-Karls University, Tübingen, Germany.
Purpose: This study explores the potential interaction of brolucizumab with platelets and its effects on platelet activation and reactivity, crucial in retinal vasculitis and retinal vascular occlusion. Safety concerns remain of interest, although brolucizumab showed superior retinal efficacy and reduced injection frequency compared to other licensed anti-VEGF agents.
Methods: Resting and activated platelets of healthy volunteers were pretreated with brolucizumab at the following concentrations 0.
A comprehensive overview of tolerogenic vaccine adjuvants and their modes of action.
Front Immunol
January 2025
Amgen Research, Amgen Inc., South San Francisco, CA, United States.
Article Synopsis
- Tolerogenic vaccines aim to create immune tolerance specifically for disease-related antigens, offering a safer alternative to broad immunosuppression, which can lead to infections and weakened anti-tumor responses.
- They work by promoting certain immune cells that help regulate and suppress harmful immune responses, thus targeting conditions like autoimmunity and transplant rejection.
- The design of these vaccines varies, often involving a relevant antigen paired with a tolerogenic adjuvant that enhances their effectiveness by creating a more favorable immune response through multiple mechanisms.
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile.
Front Immunol
January 2025
Polpharma Biologics S.A., Gdansk, Poland.
Background: Biosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in healthy subjects and patients with relapsing-remitting MS (RRMS) to confirm a matching immunogenicity profile between biosim-NTZ and ref-NTZ.
Methods: Immunogenicity of biosim-NTZ versus ref-NTZ was evaluated in two pivotal clinical studies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!